Menu
Begin main content
Home About CADTH What We Do Programs and Services CADTH Common Drug Review Reports ataluren
Back to Programs and Services

CADTH Common Drug Review

ataluren

Last Updated: March 5, 2019
Result type: Reports
Project Number: SR0607-000
Product Line: Common Drug Review

Generic Name: ataluren

Brand Name: Translarna

Manufacturer: PTC Therapeutics Canada ULC

Indications: Dystrophinopathy

Manufacturer Requested Reimbursement Criteria1:

​For the treatment of dystrophinopathy resulting from a nonsense mutation in the dystrophin gene.

Submission Type: New

Project Status: Cancelled

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.